This is a sequencing-risk stock. The demand backdrop is attractive and AI does not commoditize Rocket Lab's core product, but the company still must clear
Neutron proof, absorb high
capex, and complete Iridium on acceptable terms. Because the starting valuation is already rich, even good operating progress can produce mediocre equity returns if the mix stays contractor-like or if execution slips by a few quarters.